You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH):預計半年度歸母淨利潤同比增長約101.92%

格隆匯7月10日丨藥明康德(603259.SH)公佈,1、公司預計2025年半年度實現營業收入約人民幣2,079,928萬元,同比增長約20.64%,其中持續經營業務收入同比增長約24.24%。2、公司預計本期實現經調整非《國際財務報告準則》下歸屬於本公司股東的淨利潤(以下簡稱“經調整歸母淨利潤”)約人民幣631,480萬元,同比增長約44.43%。3、公司預計本期實現歸屬於本公司股東的扣除非經常性損益的淨利潤約人民幣558,213萬元,同比增長約26.47%,與經調整歸母淨利潤增速相比主要受到匯率波動的影響。4、公司預計本期實現歸屬於本公司股東的淨利潤約人民幣856,088萬元,同比增長約101.92%,其中包含了出售聯營公司部分股權所獲得的投資收益;本期基本每股收益預計約人民幣3.01元/股,同比增長約106.16%。

公司持續聚焦獨特的“一體化、端到端”CRDMO(合同研究、開發與生產)業務模式,緊抓客戶對賦能需求的確定性,不斷拓展新能力、建設新產能,持續優化生產工藝和提高經營效率,推動業務持續穩健增長,高效極致賦能客戶並致力於將更多新藥、好藥帶給全球病患。本期非經常性損益項目對利潤的影響主要來自於出售持有的WuXiXDCCaymanInc.部分股票的收益,本期預計收益約人民幣320,986萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account